Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propranolol dynamics in thyrotoxicosis

J Feely, I H Stevenson, J Crooks

    Clinical Pharmacology and Therapeutics
    |July 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drugs in Hospital.

    Journal of the Royal College of Physicians of London·2019
    Same author

    A positive Monospot test in a diabetic with sarcoidosis.

    Irish journal of medical science·2016
    Same author

    The application of the fast, multi-hit, pixel imaging mass spectrometry sensor to spatial imaging mass spectrometry.

    The Review of scientific instruments·2012
    Same author

    The effect of fluphenazine on steady state plasma levels of nortriptyline.

    British journal of clinical pharmacology·2012
    Same author

    A survey of patients' attitudes to clinical research.

    Irish medical journal·2011
    Same author

    Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

    Irish journal of medical science·2011
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Propranolol effectively reduced heart rate and triiodothyronine levels in thyrotoxic patients. Higher plasma propranolol concentrations correlated with greater reductions in heart rate and T3, and influenced weight changes.

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Thyrotoxicosis is a condition characterized by excessive thyroid hormones.
    • Beta-blockers like propranolol are used to manage symptoms of hyperthyroidism.

    Purpose of the Study:

    • To evaluate the efficacy of propranolol in treating thyrotoxicosis.
    • To investigate the relationship between plasma propranolol levels and therapeutic outcomes.

    Main Methods:

    • Twenty-five thyrotoxic patients received propranolol (160 mg/day) for 1-2 weeks.
    • Measurements included heart rate (supine and exercise), sitting pulse rate, serum triiodothyronine (T3), and serum thyroxine.
    • Plasma propranolol levels were measured and correlated with clinical and biochemical parameters.

    Main Results:

    Related Experiment Videos

    • Propranolol significantly reduced heart rates and sitting pulse rate.
    • Serum T3 levels decreased significantly, while serum thyroxine levels remained unchanged.
    • Plasma propranolol levels positively correlated with reductions in heart rate, pulse rate, and serum T3.
    • Weight changes were also related to plasma propranolol concentration.

    Conclusions:

    • Propranolol is effective in managing thyrotoxicosis symptoms by reducing heart rate and T3 levels.
    • Therapeutic response and weight changes are dose-dependent, correlating with plasma propranolol concentrations.